Company Announcements - 2018
PeriCoach Expands Clinical Indication to Include Pelvic Organ Prolapse2 May 2018
Analytica is pleased to announce that it has received Australian TGA clearance for the expanded clinical indication for the PeriCoach System to assist in the conservative treatment of Pelvic Organ Prolapse.
Appendix 4C30 April 2018
Analytica presents its quarterly cash flow report to 31 March 2018.
Change in PeriCoach Manufacturer for US Market. Reduction in Cost of Goods.23 March 2018
Analytica is selecting a new manufacturer for its PeriCoach product in the US market following the decision by the product’s previous manufacturer of record to withdraw USFDA registration.
Appendix 4D28 February 2018
Analytica presents its Appendix 4D - Half year results to 31 December 2017.
Appendix 3Y (x3) and Form 6049 February 2018
Change of Director's Interest Notice for Dr Michael Monsour, Dr Peter Corr, and Mr Ross Mangelsdorf, and Form 604 for Dr Michael Monsour.
Analytica Raises $1.039M7 February 2018
Analytica has raised $1.039M of capital from shareholders exercising their options and from private placements.
Senate Inquiry Submission30 January 2018
Analytica presents the Company’s submission to the Australian Senate Committee “Inquiry into the number of women in Australia who have had transvaginal mesh implants and related matters”.
Appendix 4C29 January 2018
Analytica presents its quarterly cash flow report for the period ending 31 Dec 2017.